Tradestie Institutional Equity Comparison Engine
MDEV vs FTXH โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
FTXH Overall Edge
FTXH Captures Institutional Edge (2โ0 Pillars ยท 3โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to First Trust Nasdaq Pharmaceuticals ETF (FTXH) driven by superior Momentum & Technical, Options & Structure. Fundamentally, MDEV trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus FTXH at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, MDEV sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against FTXH sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
MDEV N/M vs FTXH N/M Fwd P/E
Growth & Margin Winner
Tie
Op Margin N/A vs N/A ยท YoY N/A vs N/A
Momentum & Technical Winner
FTXH
1Y +10.2% vs +39.2% ยท 52W Pos 86% vs 91%
Options & Structure Winner
FTXH
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (50th %ile IV)
MDEV
Cboe BZX
First Trust Indxx Medical Devices ETF
Institutional Equity
$22.56
-0.33% 1D
Market Cap
N/A
1M Return
+5.76%
1Y Return
+10.17%
Forward P/E
N/M
Unified AI Score
41.2 / 100
SELL
Tech 31.0
Fund 43.0
Flow 50.0
Mom 50.0
FTXH
NASDAQ
First Trust Nasdaq Pharmaceuticals ETF
Institutional Equity
$43.87
-0.81% 1D
Market Cap
N/A
1M Return
+5.3%
1Y Return
+39.25%
Forward P/E
N/M
Unified AI Score
50.1 / 100
HOLD
Tech 43.0
Fund 45.0
Flow 50.0
Mom 41.1
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
MDEV +10.17%
FTXH +39.25%
Spread: +30.9 pp (FTXH Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
MDEV TTM Op. Margin: N/A
FTXH TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MDEV vs FTXH. Trailing 12-month operating profitability (MDEV N/A vs FTXH N/A) and valuation multiples (MDEV N/M vs FTXH N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MDEV | FTXH | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | N/A | Larger Scale | Tie |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | N/A | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | N/A | N/A | Higher Margin | Tie |
| Net Profit Margin Profitability | N/A | N/A | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | N/A | N/A | Higher ROE | Tie |
| 52-Week Range Position Momentum | 86% ($18โ$23) | 91% ($31โ$45) | Stronger Trend | FTXH |
| Beta / 30D Volatility Risk Regime | 0.55ฮฒ ยท 25% Vol | 0.46ฮฒ ยท 22% Vol | Lower Realized Risk | FTXH |
| Unified Institutional Score Composite Signal | 41.2 / 100 (SELL) | 50.1 / 100 (HOLD) | Higher Composite | FTXH |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full MDEV vs FTXH Buy Guide
MDEV
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
FTXH
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
50th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither MDEV nor FTXH registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.